Search This Blog

Tuesday, July 9, 2024

'ED Boarding Didn't Always Lead to Psychiatric Inpatient Stay for Youths'

 Almost half of youths who boarded in the emergency department awaiting inpatient psychiatric care were never admitted to such a facility, according to a cross-sectional study from Massachusetts.

Of 4,942 episodes of youth boarding in the ED for 3 or more midnights, just 56% resulted in inpatient admission, and certain groups were less likely to get to that point, Lindsay Overhage, an MD/PhD student at Harvard University, and colleagues reported in JAMA Pediatricsopens in a new tab or window.

"There are just a lot of kids who were boarding for a really long time," Overhage told MedPage Today. "That's kind of unique in psychiatry from other areas of medicine. If you're the sickest person with an infection, you're going to be the first person to go to a medical floor [or] the [intensive care unit]. It's kind of the opposite in psychiatry, where if you have some of the worst symptoms, you're actually waiting the longest for a bed."

A smaller proportion of transgender and nonbinary youth received inpatient care compared with cisgender females, who had the highest rates of admission (51% vs 59%), and regression analyses showed a -9.1 percentage point difference (-14.7 to -3.6), they reported.

A similar pattern occurred for Black youth compared with white youth (51% vs 56%), with a -4.3 percentage point difference (-8.4 to -0.2) in regression analyses, the authors found.

Transgender and nonbinary youth also had longer mean boarding times compared with cisgender females (10.4 versus 8.6 midnights), they reported.

"It's critical that we look more at why these disparities are happening and what policy changes we can make," Overhage said, noting that transgender and nonbinary youth are often required to have a single room, which limits the available inpatient beds in many hospitals in the state.

For their study, Overhage and colleagues used statewide administrative data collected from the Expedited Psychiatric Inpatient Admission database from May 2020 to June 2022. They included all patients ages 5 to 17 who boarded in Massachusetts-based EDs for at least 3 midnights while waiting for inpatient psychiatric care.

Overall, 54% of boarding episodes involved cisgender females, 40% involved cisgender males, and 7% involved transgender or nonbinary youth. Regarding race, 44% of episodes involved white youth, 16% Hispanic youth, and 15% Black youth, while race was unknown for 18%.

The most common diagnosis was depression (43%), followed by post-traumatic stress disorder (11%), and impulse control or conduct disorder (9%). Notably, an unspecified "other" was the second most common diagnosis (15%).

The median length of boarding for all youth in the study was 7 midnights, and 10% of all youth experienced boarding episodes that lasted for 17 or more midnights. Kids 12 and under were boarded disproportionately longer and admitted less frequently than adolescents, the researchers noted.

The main barriers to placement were bed availability or no barriers (66%) and aggression or assaultive risk (12%), which included some of the most high-need patients.

Also, youth with psychotic disorders or depression were admitted more frequently than those with impulse control/conduct disorders or developmental disorders.

The study was limited by several factors, including the fact that the results may not be generalizable because the study only analyzed data from Massachusetts. They also noted that the study only included boarding data from the 30 months after the start of the COVID-19 pandemic, and the most recent data in the analysis was from 2022.

Still, the researchers concluded that the data can "help guide further research and development of policies to reduce boarding and ensure equity in access to inpatient care."

They also noted that while the "high prevalence of boarding suggests a need for more inpatient child psychiatry beds," boarding is also a "symptom of unmet need across the continuum of care. Reducing boarding will also require innovation and resources in outpatient care and non-ED crisis support."

Disclosures

The study was funded by the Manton Foundation, the National Institute of Mental Health, the National Institute of Aging, and the Brain & Behavior Research Foundation Young Investigator Grant.

Overhage reported receiving grants from the Manton Foundation, the National Institute for Mental Health, and the National Institute of Aging outside the submitted work. Co-authors reported receiving grants from the Agency for Healthcare Research and Quality, the Brain & Behavior Research Foundation, and serving on the Epic Behavioral Health Specialty Steering Board.

Primary Source

JAMA Pediatrics

Source Reference: opens in a new tab or windowOverhage LN, et al "Disparities in psychiatric emergency department boarding of children and adolescents" JAMA Pediatr 2024; DOI: 10.1001/jamapediatrics.2024.1991.


https://www.medpagetoday.com/psychiatry/generalpsychiatry/111006

Athira Last Patient Completed Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s

 Reporting of Topline Results Targeted by End of Third Quarter 2024

Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain

Athira Pharma, Inc (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the completion of dosing for the last patient in the Phase 2/3 LIFT-AD clinical trial evaluating fosgonimeton in people with mild-to-moderate Alzheimer’s disease (AD). The Company is now targeting to report topline results from the LIFT-AD trial by the end of the third quarter of 2024 and has been invited to discuss the fuller data set during an oral presentation on October 29, 2024, at the 17th Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place from October 29 – November 1, 2024, in Madrid, Spain.

https://www.globenewswire.com/news-release/2024/07/09/2910213/0/en/Athira-Pharma-Announces-Last-Patient-Completed-LIFT-AD-Clinical-Trial-of-Fosgonimeton-in-Mild-to-Moderate-Alzheimer-s-Disease.html

'NBC Parkinson's Expert Says Biden Has "Hallmarks"'

 Corporate media's marching orders to help oust President Joe Biden have intensified - as NBC News just interviewed Parkinson's expert Dr. Tom Pitts, who says that Biden has several "hallmarks" of the disease, after news broke in the last few days that a Parkinson's specialist has visited the White House at least 8 times in the past year.

"Do you notice anything that gives you a red flag, as a doctor?" asked host Tom Llamas.

"Oh yeah, I see him 20 times a day in the clinic, I mean, it's ironic because he has the classic features of neurodegeneration - I mean, word-finding difficulties..." Pitts replied.

Llamas asked if Biden overcoming a stutter could account for the affects - to which Pitts, a Democrat, replied, "no, this is not a palatal issue, or a speech discrepancy," adding that Biden has issues with "actual word retrieval," not to mention "rigidity" issues such as "loss of arm swing," adding "you notice when he turns it's sort of end-block turning, it's not a quick turn."

"That's one of the hallmarks of Parkinson's," he continued. "I could diagnose him from across the mall."

Watch:

He's also been giving creepy arm rubs lately, though not sure that's a sign of Parkinson's.

 

Abbott faces trial over claims that preterm infant formula caused dangerous disease

 Similac baby formula maker Abbott is expected to face a trial on Monday over claims that its formula for preterm infants used in neonatal intensive care units causes a potentially deadly bowel disease, the second trial out of hundreds of similar lawsuits in the United States.

Lawyers for the company and for Illinois resident Margo Gill will make their opening statements to jurors in St. Louis, Missouri, and the trial is expected to last most of the rest of the month. Gill alleges in the lawsuit that her premature infant child developed necrotizing enterocolitis (NEC) as a result of being fed Abbott's products for premature babies.

NEC, which causes the death of bowel tissue, mostly affects newborns and has a fatality rate of between 15% and 40%. Gill's child survived, but suffers long-term health problems, according to the lawsuit.

Like all of the lawsuits over NEC, the case involves formula and products for fortifying mother's milk given to infants in hospital settings, not ordinary formula available to consumers in stores.

"Specialized formulas and fortifiers, like the one in this case, are considered part of the standard of care by the medical community and, along with human milk, are the only available options to feed premature infants," Abbott said in a statement.

The company said that Gill's child "suffered from a traumatic brain injury in utero and at birth, long before she was fed any Abbott products," and that "no one is to blame" for her condition.

Close to 1,000 lawsuits have been filed against Abbott, Enfamil formula maker Reckitt Benckiser or both in federal or state courts alleging that cow's milk-based formula products for premature infants caused NEC. More than 500 are centralized in an Illinois federal court, with others pending in Illinois, Missouri and Pennsylvania.

The lawsuits claim that the companies failed to warn that infants given their products are at greater risk of NEC compared to infants who are breast-fed or given donor milk or human milk-derived formula.

Reckitt and a lawyer for the plaintiffs did not immediately comment.

The first lawsuit to go to trial, against Reckitt in Illinois, ended with a $60 million jury verdict in March. Reckitt is appealing that verdict and has argued that the plaintiff's case relied on unsound expert testimony.

The litigation has concerned investors. Reckitt's share price fell about 15% after the verdict, and Abbott's about 4%. Both stocks have remained depressed, although analysts at JPMorgan and Barclays have said they believe the companies' ultimate liability is likely to be small.

The NEC Society, a patient-led non-profit organization working to combat the disease, has criticized the lawsuits, saying that "feeding decisions should be made at patients' bedsides, not in courtrooms." The group has no financial or other relationship with Abbott or Reckitt, according to a spokesperson.

The NEC lawsuits are separate from ongoing litigation against Abbott over the shutdown of its Sturgis, Michigan, plant and subsequent recall of batches of baby formula for possible contamination, which contributed to a nationwide formula shortage in 2022. There have been no trials in those cases.

https://www.yahoo.com/news/abbott-faces-trial-over-claims-100432384.html

Tempus AI started at Buy at 9 sell siders

 

TodayInitiatedWilliam BlairOutperform
TodayInitiatedTD CowenBuy$50
TodayInitiatedStifelBuy$45
TodayInitiatedNeedhamBuy$47
TodayInitiatedMorgan StanleyOverweight$44
TodayInitiatedLoop CapitalBuy$48
TodayInitiatedLongbowBuy$48
TodayInitiatedJP MorganOverweight$42
TodayInitiatedBofA SecuritiesBuy$41

Bidenomics? Business Bankruptcies Jump 34% In First Half Of 2024

 by Naveen Athrappully via The Epoch Times,

Bankruptcy filings by commercial entities grew by more than a third this year as businesses struggled under an environment of high costs and interest rates, according to the American Bankruptcy Institute (ABI).

A total of 3,016 commercial Chapter 11 bankruptcies were filed in the January–June period this year, up 34 percent from last year, said a July 3 ABI press release. Small-business filings rose by 61 percent. Total bankruptcy filings rose by 15 percent, with individual filings increasing by 15 percent.

The continued increase in bankruptcy filings reflects the growing economic strain on businesses and households,” said ABI Executive Director Amy Quackenboss.

Michael Hunter, vice president of bankruptcy data provider Epiq AACER, said he expects an increase in individual filings ahead, “especially considering the large increase in commercial filings, consumer debt levels, high interest rates, and overall increased costs with relatively flat household income.”

Businesses have been battered in an environment of high inflation and high interest rates. The 12-month inflation rate has been hovering above 3 percent since June last year, although some analysts calculate that it maybe much higher than that. Meanwhile, the Federal Reserve has kept interest rates within a range of 5.25–5.5 percent since July last year. This combination of higher expenses is putting pressure on businesses.

Despite such an environment, many executives remain positive about the future. A recent survey by professional services network Grant Thornton found that 58 percent of chief financial officers (CFOs) are optimistic about the U.S. economy, the highest in almost three years.

Three in four CFOs expect their net profits to grow over the next 12 months, with 69 percent expecting revenues to rise.

The Q2 Small Business Index survey from the U.S. Chamber of Commerce showed that almost three-quarters of respondents foresee their revenues increasing next year. More than half cited inflation as the top challenge they face.

Bankruptcies and Interest Rates

According to S&P Global, there have been 275 corporate bankruptcy filings in the United States so far this year until May. This is slightly lower than the 277 filings in 2023 during the same period. However, it is the second-highest filing number during the January–May period since 2011.

S&P’s bankruptcy numbers, however, only take into account large companies exceeding certain asset and liability thresholds.

Some of the largest bankruptcies so far this year involving companies with more than $1 billion in liabilities include IT firm Dynata, seafood chain Red Lobster, biotechnology company Invitae Corp., and Enviva, the world’s largest industrial biomass producer.

Companies in the consumer discretionary sector accounted for the most number of bankruptcies this year, followed by health care, industrials, consumer staples, IT, and financials.

Apparel retailer Bob’s Stores recently filed for bankruptcy and announced shutting down all stores nationwide, citing difficulty in maintaining operations after its primary lender stopped funding them.

Specialty fashion retailer Rue21 filed for bankruptcy in May. Back in April, Express Inc., which dealt in casual office attire, filed for bankruptcy. In addition, fabrics and crafts retailer Joann and cosmetics brand The Body Shop also ceased operations in the United States.

In May, S&P Global attributed the high bankruptcy filings to interest rates.

“Fading hopes of lower interest rates are likely contributing to the increase in filings, as companies that may have held out hope for rate cuts at the beginning of the year come to terms with the reality that they will remain higher for longer,” it said.

The Fed has not announced an exact schedule for rate cuts. During the recently concluded policy-making meeting of the Federal Open Market Committee in June, Fed members suggested that if inflation remained elevated, they may even raise the rates.

Policymakers have no plans on cutting down interest rates until they have “greater confidence” that inflation is heading down to the target of 2 percent, according to minutes from the meeting.

However, officials admitted that implementing tighter monetary policies could result in “deteriorating household financial positions, especially for lower-income households,” which could end up having a “larger negative effect on economic activity than the staff anticipated.”

https://www.zerohedge.com/personal-finance/bidenomics-business-bankruptcies-jump-34-first-half-2024